Literature DB >> 27698870

Association of FOXM1 expression with tumor histology and prognosis in Wilms tumor: Potential for a new prognostic marker.

Nadja Apelt1, Jochen Hubertus1, Doris Mayr2, Norbert Graf3, Rhoikos Furtwängler3, Dietrich Von Schweinitz1, Roland Kappler1.   

Abstract

Wilms tumor (WT) is the most common pediatric renal malignancy. A recent ontogenic model suggests that undifferentiated tumor state, and hence poor prognosis, in WT is determined by stabilization of β-catenin in the nucleus. Forkhead box M1 (FOXM1) is a downstream component of the Wnt pathway and promotes nuclear localization of β-catenin. As elevation of FOXM1 gene expression is prognostic in various types of malignancy, we hypothesized that high FOXM1 expression in WT is associated with undifferentiated histology and thus poor prognosis. In the current study, the expression of FOXM1 mRNA was determined in 46 WT specimens and 11 renal tissue controls from patients undergoing tumor nephrectomy, and these data were assessed with regard to clinicopathological parameters. The results demonstrated an upregulation of FOXM1 in WT by 10-fold compared to normal tissue. Expression differed significantly between controls and tumors of intermediate- and high-risk histopathology (P<0.001, Kruskal-Wallis), and distinguished normal tissue from tumors of good and adverse clinical outcome (P<0.001, Kruskal-Wallis). Notably, FOXM1 expression was significantly lower (P=0.009) in patients that received preoperative doxorubicin. These results suggest that FOXM1 may serve as a companion diagnostic factor for doxorubicin-based therapies in WT.

Entities:  

Keywords:  FOXM1; Wilms tumor; forkhead box; nephroblastoma; prognosis

Year:  2016        PMID: 27698870      PMCID: PMC5038485          DOI: 10.3892/ol.2016.4958

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  14 in total

1.  A new mathematical model for relative quantification in real-time RT-PCR.

Authors:  M W Pfaffl
Journal:  Nucleic Acids Res       Date:  2001-05-01       Impact factor: 16.971

2.  Reduction of postoperative chemotherapy in children with stage I intermediate-risk and anaplastic Wilms' tumour (SIOP 93-01 trial): a randomised controlled trial.

Authors:  J de Kraker; N Graf; H van Tinteren; F Pein; B Sandstedt; J Godzinski; M F Tournade
Journal:  Lancet       Date:  2004 Oct 2-8       Impact factor: 79.321

Review 3.  Wilms tumor--a renal stem cell malignancy?

Authors:  Naomi Pode-Shakked; Benjamin Dekel
Journal:  Pediatr Nephrol       Date:  2011-04-16       Impact factor: 3.714

4.  FOXO and FOXM1 in cancer: the FOXO-FOXM1 axis shapes the outcome of cancer chemotherapy.

Authors:  Miranda S C Wilson; Jan J Brosens; Helma D C Schwenen; Eric W-F Lam
Journal:  Curr Drug Targets       Date:  2011-08       Impact factor: 3.465

Review 5.  Cancer genetics and genomics of human FOX family genes.

Authors:  Masuko Katoh; Maki Igarashi; Hirokazu Fukuda; Hitoshi Nakagama; Masaru Katoh
Journal:  Cancer Lett       Date:  2012-09-27       Impact factor: 8.679

6.  Altered expression of imprinted genes in Wilms tumors.

Authors:  Jochen Hubertus; Martin Lacher; Marietta Rottenkolber; Josef Müller-Höcker; Michael Berger; Maximilian Stehr; Dietrich von Schweinitz; Roland Kappler
Journal:  Oncol Rep       Date:  2010-12-20       Impact factor: 3.906

Review 7.  Wilms tumor.

Authors:  Andrew M Davidoff
Journal:  Adv Pediatr       Date:  2012

Review 8.  Children's Oncology Group's 2013 blueprint for research: renal tumors.

Authors:  Jeffrey S Dome; Conrad V Fernandez; Elizabeth A Mullen; John A Kalapurakal; James I Geller; Vicki Huff; Eric J Gratias; David B Dix; Peter F Ehrlich; Geetika Khanna; Marcio H Malogolowkin; James R Anderson; Arlene Naranjo; Elizabeth J Perlman
Journal:  Pediatr Blood Cancer       Date:  2012-12-19       Impact factor: 3.167

Review 9.  Targeting FOXM1 in cancer.

Authors:  Marianna Halasi; Andrei L Gartel
Journal:  Biochem Pharmacol       Date:  2012-10-24       Impact factor: 5.858

10.  Selective methylation of CpGs at regulatory binding sites controls NNAT expression in Wilms tumors.

Authors:  Jochen Hubertus; Ferdinand Zitzmann; Franziska Trippel; Josef Müller-Höcker; Maximilian Stehr; Dietrich von Schweinitz; Roland Kappler
Journal:  PLoS One       Date:  2013-06-25       Impact factor: 3.240

View more
  2 in total

1.  Identification of a five-mRNA signature as a novel potential prognostic biomarker in pediatric Wilms tumor.

Authors:  Xiao-Dan Lin; Yu-Peng Wu; Shao-Hao Chen; Xiong-Lin Sun; Zhi-Bin Ke; Dong-Ning Chen; Xiao-Dong Li; Yun-Zhi Lin; Yong Wei; Qing-Shui Zheng; Ning Xu; Xue-Yi Xue
Journal:  Mol Genet Genomic Med       Date:  2019-11-07       Impact factor: 2.183

2.  Integrated Analysis of the lncRNA-Associated ceRNA Network in Wilms Tumor via TARGET and GEO Databases.

Authors:  Biao An; Yuan Hu; Xiao Liang
Journal:  Genet Res (Camb)       Date:  2022-08-31       Impact factor: 1.375

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.